Targets › CYP19A1
32 programs from 30 companies in 139 trials: 62 Phase 2, 31 Phase 3, 26 Phase 4, 20 Phase 1; Oncology, Genitourinary, Metabolic and endocrine; next expected readout Nov 2026.
A cytochrome P450 monooxygenase that catalyzes the conversion of C19 androgens, androst-4-ene-3,17-dione (androstenedione) and testosterone to the C18 estrogens, estrone and estradiol, respectively. Catalyzes three successive oxidations of C19 androgens: two conventional oxidations at C19 yielding 19-hydroxy and 19-oxo/19-aldehyde derivatives, followed by a third oxidative aromatization step that involves C1-beta…. (UniProt, P11511)
Open in Phaseline: the race on CYP19A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of California, San Francisco | Intravenous TXA Interleukin-23 inhibitor | ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4 | Phase 4 | Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke … | Dec 2026 |
| Gangnam Severance Hospital | Aromatase inhibitors Aromatase inhibition | CYP19A1 | Phase 4 | Breast Cancer | Jan 2031 |
| National Cancer Institute (NCI) | Anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 3 | Breast Ductal Carcinoma In Situ; Breast Adenocarcinoma | Jan 2027 |
| National Cancer Institute (NCI) | Exemestane Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 3 | Breast Ductal Carcinoma In Situ; Anatomic Stage III Breast Cancer AJCC v8; Breast Adenocarcinoma | Jan 2027 |
| Alliance for Clinical Trials in Oncology | anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 3 | Estrogen Receptor-positive Breast Cancer | Apr 2027 |
| Georgios Papadakis | Anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 3 | Klinefelter Syndrome | Apr 2027 |
| IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | Anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 3 | Breast Cancer | Jun 2028 |
| University of Virginia | Anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 3 | Breast Cancer Female | Jun 2029 |
| Azienda Ospedaliero-Universitaria Careggi | anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 3 | Breast Cancer | Mar 2030 |
| NRG Oncology | Anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 3 | Stage I Breast Cancer | Apr 2031 |
| NRG Oncology | Aromatase Inhibitor (AI) Aromatase inhibitor - reduces estrogen production | CYP19A1 | Phase 3 | Breast Cancer | Jan 2032 |
| Institute of Cancer Research, United Kingdom | Anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 3 | Breast Cancer | Apr 2034 |
| ReproNovo Aps | Leflutrozole, Dose 1 Aromatase inhibitor | CYP19A1 | Phase 2 | Semen Quality | Nov 2026 |
| Hebei Medical University Fourth Hospital | Aromatase inhibitor Aromatase inhibitor (estrogen synthesis inhibitor) | CYP19A1 | Phase 2 | Breast Cancer | Dec 2026 |
| Washington University School of Medicine | Anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 2 | Breast Cancer | Jan 2027 |
| Jose Pablo Leone | Anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 2 | Male Breast Cancer | Apr 2027 |
| UNC Lineberger Comprehensive Cancer Center | anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 2 | Breast Cancer | Apr 2027 |
| Dartmouth-Hitchcock Medical Center | Anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 2 | Breast Cancer | Aug 2027 |
| Centre Leon Berard | Anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 2 | Low Grade Endometrial Stromal Sarcoma | Jan 2028 |
| Wake Forest University Health Sciences | Anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 2 | Female Breast Carcinoma | Jun 2028 |
| Medical College of Wisconsin | Aromatase inhibitors Aromatase inhibitor | CYP19A1 | Phase 2 | Breast Cancer | Sep 2028 |
| University of California, Irvine | Anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 2 | Breast Cancer | Dec 2028 |
| University of Miami | Anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 2 | Breast Cancer | Jul 2029 |
| Memorial Sloan Kettering Cancer Center | anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 2 | Breast Cancer | Mar 2030 |
| UNICANCER | Anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 2 | Breast Cancer | Nov 2030 |
| Institut Cancerologie de l'Ouest | Anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 2 | Ductal Carcinoma in Situ | Aug 2033 |
| International Cancer Research Group, United Arab Emirates | Anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 2 | Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer | – |
| Shayna Showalter, MD | anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 2 | Breast Cancer Female | – |
| Martin Blomberg Jensen | Leflutrozole Aromatase inhibitor | CYP19A1 | Phase 1 | Infertility Due to Azoospermia | May 2027 |
| Icahn School of Medicine at Mount Sinai | Anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 1 | Breast Neoplasms | Jul 2027 |
| Rovi Pharmaceuticals Laboratories | Letrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 1 | Hormone Receptor Positive Early Breast Cancer; Polycystic Ovary Syndrome; Abortion in First Trimester; Miscarriage in First Trimester … | May 2028 |
| Northwestern University | Anastrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 1 | Inguinal Hernia Unilateral | Jul 2028 |
Breast Cancer (29) Breast Cancer Female (4) Breast Ductal Carcinoma In Situ (3) Breast Adenocarcinoma (3) Nicotine Dependence (3) Endometrial Cancer (3) Psoriasis Vulgaris (2) Cytomegalovirus (CMV) (2) Ectopic Pregnancy (2) Stage I Breast Cancer (2) Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer (2) Endometrial Neoplasms (2)
small molecule (22), protein or peptide (6), mixed (4)
National Cancer Institute (NCI) (2) NRG Oncology (2) Shayna Showalter, MD (1) Icahn School of Medicine at Mount Sinai (1) IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy (1) Medical College of Wisconsin (1) Institute of Cancer Research, United Kingdom (1) Institut Cancerologie de l'Ouest (1) Wake Forest University Health Sciences (1) Dartmouth-Hitchcock Medical Center (1) Azienda Ospedaliero-Universitaria Careggi (1) Memorial Sloan Kettering Cancer Center (1) University of California, San Francisco (1) University of California, Irvine (1) University of Miami (1) Hebei Medical University Fourth Hospital (1) University of Virginia (1) Washington University School of Medicine (1) Jose Pablo Leone (1) ReproNovo Aps (1)
ADRB2 (1) AGTR1 (1) IL12B (1) IL23A (1) PDCD1 (1) NR3C1 (1) HTR2A (1) MAP2K1 (1) MAP2K2 (1) MS4A1 (1) CHRM3 (1) CHRM2 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.